Dr. de Rus Jacquet is a researcher in the Neurosciences axis of the CHU de Québec-Université Laval Research Center, and assistant professor in the Department of Psychiatry and Neurosciences in the Faculty of Medicine at Université Laval. She obtained her PhD in Medicinal Chemistry and Molecular Pharmacology from Purdue University (USA) in 2016, during which she undertook an ethnopharmacological approach rooted in the valorization of First Peoples’ knowledge and discovered neuroprotective botanicals that attenuated Parkinson’s disease-related pathology. She then joined the Howard Hughes Medical Institute to train in the use of induced pluripotent stem cells (iPSCs) in the laboratory of Dr. Randall Moon (2016-2017, Institute for Stem Cell and Regenerative Medicine, University of Washington, USA). Subsequently, she completed two postdoctoral trainings on the neurobiology of Parkinson’s disease with Dr. Erin O’Shea (2017-2020, Howard Hughes Medical Institute, USA), and with Dr. Francesca Cicchetti (2020-2023, Université Laval, Canada). Her work has highlighted the role of glial cells, and astrocytes in particular, in the progression of Parkinson’s disease.
Dr. de Rus Jacquet’s team is working to better understand the cellular and molecular mechanisms underlying neurodegenerative diseases, and in particular Parkinson’s disease. She is also interested in developing culturally-appropriate approaches to healthcare to improve the quality of life of First Peoples’ patients suffering from these devastating diseases.
The fundamental role of glial cells in Parkinson’s disease
How do neuronal and non-neuronal cells interact? How is immune communication between the brain and the periphery regulated, and what is the role of the blood-brain barrier? What changes occur in Parkinson’s disease that alter this fine-tuned balance? These fundamental questions are being investigated using state-of-the-art modeling approaches (iPSCs, organ-on-chip, organoids) that enable us to reproduce the complexity of the brain in the laboratory.
Natural health products and culturally safe healthcare for healthy aging
Thanks to collaborations with neurologist colleagues and members of First Peoples communities, the laboratory is interested in better understanding the benefits and risks associated with the use of natural health products and food-derived polyphenols to mitigate symptoms associated with neurodegenerative diseases.
This work is funded by the Parkinson’s Foundation, Réseau Parkinson Québec, INAF and Fondation CHU de Québec.
CHUL
2705, boulevard Laurier
R-3701
Québec, QC
Canada G1V 4G2
Latest news
Data not available
- Alves Martins Borba, Flavia NataleDoctoral studentCHUL+1 418-525-4444, extension 42296flavia.borba@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-3701
Québec, QC
Canada G1V 4G2 - Arevalo, OcéaneMaster studentCHUL+1 418-525-4444, extension 42296oceane.arevalo.1@ulaval.caoceane.arevalo@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-3701
Québec, QC
Canada G1V 4G2 - Boutin, MartineEmployeeCHUL+1 418-525-4444, extension 42296martine.boutin@crchudequebec.ulaval.camartine_boutin@hotmail.com
2705, boulevard Laurier
R-3701
Québec, QC
Canada G1V 4G2 - Diadhiou, SandraDoctoral studentCHUL+1 418-525-4444, extension 42296sandra.diadhiou@crchudequebec.ulaval.ca
2705, boulevard Laurier
T2-50
Québec, QC
Canada G1V 4G2 - Foster, Marie-PierInternCHUL+1 418-525-4444, extension 42296marie-pier.foster.1@ulaval.ca
2705, boulevard Laurier
R-3701
Québec, QC
Canada G1V 4G2 - Jacquet, BastienEmployeeCHUL+1 418-525-4444, extension 42296bastien.jacquet.1@crchudequebec.ulaval.ca
2705, boulevard Laurier
R-3701
Québec, QC
Canada G1V 4G2
The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's disease
Journal ArticleNat Commun, 14 (1), 2023.
How nutrients and natural products act on the brain: Beyond pharmacology
Journal ArticleCell Rep Med, 4 (10), 2023.
Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons
Journal ArticleSci Rep, 12 (1), 2022.
Prompting endogenous repair of brain injury: science fiction or reality?
Journal ArticleMol Neurodegener, 17 (1), 2022.
Passive immunization against phosphorylated tau improves features of Huntington's disease pathology
Journal ArticleMol Ther, 30 (4), 2022.
The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease
Journal ArticleElife, 10 , 2021.
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience
Journal ArticleParkinsonism Relat Disord, 91 , 2021.
Correction to: Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders
Journal ArticleMol Psychiatry, 26 (7), 2021.
Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders
Journal ArticleMol Psychiatry, 26 (7), 2021.
Targeting Tau to Treat Clinical Features of Huntington's Disease
Journal ArticleFront Neurol, 11 , 2020.
Active projects
- Blueberry polyphenol metabolites: biodistribution and mechanisms of protection at the blood-brain barrier, from 2023-08-25 to 2024-03-31
- Crosstalk at the blood-brain barrier: new insights into Parkinson's disease, from 2022-06-30 to 2024-06-30
- Fonds de démarrage - Nouveau chercheur, from 2023-07-01 to 2027-06-30
- Fonds de démarrage pour chercheurs en debut de carrière - Bourse de recrutement étudiant, from 2023-07-01 to 2028-06-30
- Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
- Maladie de Parkinson et Premiers Peuples : étude évaluative des besoins neurologiques, from 2023-09-01 to 2025-02-28
- Targeting the blood-brain immune axis to prevent dissemination and progression of Parkinson’s disease, from 2023-09-25 to 2025-09-24